Catalent completes $5.5 million expansion of clinical storage at Philadelphia facility
Catalent's expanded Philiadelphia facility.
Expansion meets the demand for additional capacity to serve large-scale clinical studies and provides the space for future growth.
Catalent Pharma Solutions has completed a $5.5 million expansion program at its 200,000+ sq ft Philadelphia, Pennsylvania, site to provide additional clinical packaging and storage capacity.
The facility, which is located near many customers and major transportation hubs, is also one of the largest sites in Catalent’s global clinical supply network. The investment has provided the site with a 40% increase in pallet space for both refrigerated and ambient clinical storage, additional cold chain packaging areas, and a new clinical label control area. The building also features a new campus-wide environmental monitoring and building management system.
“The expansion not only allows us to meet the demand for additional capacity to serve large-scale clinical studies today, but also provides the space necessary for future growth,” said Albert Quintero, General Manager, Clinical Supply Services. He added: “We look forward to welcoming new and existing customers at these new facilities.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.